Aryl aniline derivatives as β2 adrenergic receptor agonists

A compound of formula (I):

• wherein:
• R1 and R2 taken together are selected from —NHC(═O)CH═CH—, —CH═CHC(═O)NH—, —NHC(═O)S—, and —SC(═O)NH—;
• R3 is hydroxy and R4 is hydrogen;
• one of R5 and R6 is —[X—C1-6alkylenyl]n—NR10R11 or C1-6alkylenyl-NR12R13,
• and the other of R5 and R6 is selected from hydrogen, hydroxy, C1-4alkoxy, and C1-4alkyl,
• wherein C1-4alkyl is optionally substituted with halo,
• wherein
• each X is independently selected from —O—, —NH—, —S—, —NHSO2—, —SO2NH—, —NHC(═O)—, and —C(═O)NH—;
• each of R10 , R11, R12, and R13 is independently hydrogen or C1-4alkyl;
• or
• R10 and R11, together with the nitrogen atom to which they are attached, or R10, together with the nitrogen atom to which it is attached and a carbon atom of the adjacent C1-6alkylenyl, or R12 and R13, together with the nitrogen atom to which they are attached, or R12, together with the nitrogen atom to which it is attached and a carbon atom of the adjacent C1-6alkylenyl, form a heterocyclic or heteroaryl ring having from 5 to 7 ring atoms, and optionally containing an additional heteroatom selected from oxygen, nitrogen, and sulfur, wherein nitrogen is optionally substituted with —S(O)2—C1-4alkyl;
• and
• n is 1,2, or 3;
• and
• each of R7, R8, and R9 is independently hydrogen or C1-6alkyl;
• or a pharmaceutically-acceptable salt or solvate or stereoisomer thereof.